Clinical Trials · NCT05851547
Dose Escalation For INtraprostatic LEsions
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Enrollment
- 54
- Start date
- Nov 2023
- Locations
- 1 site, Canada
- Primary endpoint
- Genitourinary and gastrointestinal toxicity